ドナー輸血診断市場レポート：2031年までの動向、予測、競合分析

世界のドナー輸血診断市場の将来は、血液バンク、献血市場での機会で有望視されています。世界のドナー輸血診断市場は、2025年から2031年にかけてCAGR 6.9%で成長すると予想されます。この市場の主な促進要因は、安全な輸血と輸血関連感染予防のための高度な診断検査に対する需要の増加、輸血を必要とする血液疾患や外科手術の有病率の上昇、血液検査技術の進歩や血液の安全性に関する規制基準の高まりです。

Lucintelの予測では、タイプ別では、様々なヘルスケア環境における診断キットと試薬の費用対効果と使いやすさから、キットと試薬が予測期間中に高い成長を遂げる見込みです。

用途別では、厳格な規制要件と大量の血液採取・保管により、血液バンクが高い成長を遂げると予測されています。

地域別では、厳しい規制の枠組みやヘルスケアシステムへの多額の投資により、北米が予測期間中に最も高い成長を遂げる見込みです。

150ページを超える包括的なレポートで、ビジネスの意思決定に役立つ貴重な洞察を得てください。以下に、いくつかのインサイトを含むサンプル図を示します。

ドナー輸血診断市場の新たな動向

新たな動向は、このドナー輸血診断市場の展望を電光石火の速さで変革しています。技術の進歩、規制の変更、市場のニーズがこれらの変化を促進しています。その焦点は、診断精度の向上、有害な輸血合併症リスクの低減、献血管理プロセスの最適化にあります。以下は、今日の市場における5つの主要動向です。

• 血液スクリーニングにおける人工知能の統合：ドナースクリーニング検査におけるAIベースのソリューションの導入は、診断の精度と効率を高めることを目的としています。AIアルゴリズムは継続的に学習し、ドナー血液の複雑なパターンを分析することで、病原体の特定、適合性の達成、輸血に最適な適合血液の発見に役立ちます。結果が迅速に得られ、ヒューマンエラーによるミスの可能性が最小限に抑えられるため、輸血はより安全になります。AIの進歩により、この技術はドナー輸血の診断プロセス全体を一変させ、より迅速で信頼性の高いスクリーニングをもたらすかもしれないです。
• 核酸検査の進歩：NATは、提供された血液中の病原体を特定するために不可欠なツールとして開発されました。NAT法は、HIVや肝炎などのウイルス感染を高い感度で検出できるため、輸血用血液製剤の安全性を高めることができます。ほとんどの地域で、NATは現在、日常的な検査手順の一部となりつつあり、献血された血液の質を向上させ、輸血によって感染するリスクを減らすのに役立っています。NATの使用拡大が、より安全な輸血を目指す世界の動きに大きく貢献しています。
• 自動血液スクリーニングシステムへの移行：自動化は血液スクリーニングの方法を変えつつあります。現在、多くの大量検査は、血液検査に使用される自動化されたシステムを利用することにより、非常に正確に行われています。自動化により、検査が簡単に完了し、人手によるコストが削減され、人為的ミスが最小限に抑えられるため、迅速で精度の高い検査が行われます。スクリーニングの場合、自動化されたオペレーションはスケーラビリティも向上させます。つまり、量を増やすことが容易であり、高い安全性レベルで多くの献血を行うことができます。
• 病原体不活化技術への注目：病原体不活化技術は、安全な輸血の追求のためにますます使用されるようになってきています。これは、献血血液の品質を損なうことなく、献血血液内のあらゆる病原体の存在を中和することを目的とした方法です。新たな感染症や多剤耐性菌の出現により、高度な不活化法の需要が高まっています。病原体不活化技術は、ドナー輸血の診断および処理ワークフローに不可欠なものとなりつつあります。
• 規制の変化とより高い基準：世界中の規制機関は、献血と輸血診断の要件を更新し、強化しています。より厳格なスクリーニングプロセスや診断プロセスのための新技術が献血プロセスに組み込まれつつあります。規制の変化により、市場は技術革新を余儀なくされ、より高い安全性、ひいては高品質の血液製品を提供する必要に迫られています。規制の変化は、より安全な献血の提供に役立つ革新的な診断ツールを開発する企業にも機会を提供しています。

AIの統合、核酸検査の進歩、自動化、病原体の不活化技術など、ドナー輸血診断市場における新たな動向は、血液スクリーニングの効率、精度、安全性を高めています。これらの技術革新は、診断プロセスを大幅に改善し、輸血に関連するリスクを低減し、血液管理を合理化しています。これらの動向が進化を続けるにつれて、市場は再構築され、世界中の輸血業務における安全性と業務効率の水準向上に貢献することになるでしょう。

ドナー輸血診断市場の最近の動向

ドナー輸血診断市場における最近の進歩は、現在、血液の安全性、診断、業務効率の強化がより重要視されていることを浮き彫りにしています。診断プロセスを合理化し、病原体検出能力を向上させながら、より高品質の血液製剤を確保する技術や研究投入がますます増えています。現在市場を牽引している5つの進歩は以下の通りです：

• AIベースの血液スクリーニング：人工知能は血液スクリーニング法の進歩に不可欠となっています。AIアルゴリズムは現在、献血における潜在的な不適合、異常、病原体の特定を支援しています。これにより、従来の手作業による方法と比較して、より高い精度と迅速な結果が保証されます。AIが進化し続けるにつれて、ドナー・スクリーニングと輸血の安全性を向上させる可能性が高まり、将来の血液検査イノベーションの礎となります。
• 核酸検査（NAT）の進歩：核酸検査（NAT）は、献血中のウイルス病原体をより迅速かつ正確に検出できる新しい技術により、劇的に改善されました。日常的なスクリーニングにおけるNATの使用が増えたことで、輸血によって感染するリスクが劇的に減少し、それによって世界中の輸血の安全性が全体的に向上しました。NAT技術の継続的な改良により、これらの診断ツールの検出能力はさらに向上する見込みです。
• 自動スクリーニングシステムの導入：自動血液スクリーニング・システムの採用が増加しており、処理能力が向上し、人為的ミスが最小限に抑えられることで、市場に変化が生じています。これらのシステムは処理時間を短縮し、大量の献血を効率的に検査できます。検査プロセスの自動化は、運用コストの削減、手作業に伴うリスクの最小化、血液スクリーニング手順の全体的な信頼性の向上に役立ちます。
• 病原体検出のための次世代シーケンス（NGS）：血液の高度なスクリーニングは、NGS技術を血液検査に導入して超高感度・高選択性の病原体検出を実現する第3世代シーケンサーで達成されます。例えば、希少で最近出現した病原体として広範囲に及ぶ感染症が、他よりも高い精度で同定されました。これは、これまで知られていなかった病気が急速に脅威を増しているため、提供された血液の安全性をチェックすることができます。
• より進化した血液キット：血液検査用に設計された新しい診断キットは、検査をより正確に、より速く、より安くするために作られました。このキットは、病院だけでなく遠隔地でも利用できるようになり、低開発国における輸血の安全性が向上する可能性が高まっています。

ドナー輸血診断市場における最近の進歩は、AIを活用したスクリーニング、高度な病原体検出、自動化、診断キットの改良に基づいており、血液の安全性と検査精度を向上させています。これらの技術革新はまた、運用コストと検査時間を削減し、より効率的でスケーラブルなソリューションへと市場を牽引しています。これらの技術が世界の輸血システムに統合されるにつれ、献血の全体的な安全性と管理が改善され続けると思われます。

目次

第1章 エグゼクティブサマリー

第2章 世界のドナー輸血診断市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界のドナー輸血診断市場の動向（2019～2024年）と予測（2025～2031年）
• タイプ別
  • 機器
  • キットと試薬
• 用途別
  • 血液銀行
  • 献血
  • その他

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別
• 北米
• 欧州
• アジア太平洋
• その他地域

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別
  • 用途別
  • 地域別
• 世界のドナー輸血診断市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界のドナー輸血診断市場の能力拡大
  • 世界のドナー輸血診断市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Grifols
• F. Hoffmann-La Roche
• Abbott
• Bio-Rad Laboratories
• Werfen
• Quidelortho Corporation
• Alivedx Holdings Finance
• Bag Diagnostics Gmbh
• Diasorin
• Prestige Diagnostics

The future of the global donor transfusion diagnosis market looks promising with opportunities in the blood bank, blood donation markets. The global donor transfusion diagnosis market is expected to grow with a CAGR of 6.9% from 2025 to 2031. The major drivers for this market are increasing demand for safe blood transfusions and advanced diagnostic tests to prevent transfusion-related infections, rising prevalence of blood disorders and surgical procedures requiring blood transfusions, and advancements in blood testing technologies and growing regulatory standards for blood safety.

Lucintel forecasts that, within the type category, kits and reagent is expected to witness higher growth over the forecast period due to cost-effectiveness and ease of use of diagnostic kits and reagents in various healthcare settings.

Within the application category, blood bank is expected to witness the higher growth due to stringent regulatory requirements and high volume of blood collection and storage.

In terms of region, North America is expected to witness the highest growth over the forecast period due to stringent regulatory frameworks and significant investment in healthcare systems.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Donor Transfusion Diagnosis Market

Emerging trends are transforming this donor transfusion diagnosis market landscape at a lightning pace. Technological advances, regulatory changes, and market needs are driving these changes. Their focus is on improving diagnosis accuracy, reducing the risks of adverse transfusion complications, and optimizing blood donor management processes. Here are five key trends in the market today:.

• Integration of Artificial Intelligence in Blood Screening: Increased incorporation of AI-based solutions in donor screening tests is aimed at increasing the accuracy and efficiency of diagnosis. The AI algorithm continuously learns to analyze complex patterns of donor blood that help identify pathogens, achieve compatibility, and find the best matching blood for transfusion. Since results are quickly obtained and the chance of making a mistake due to human error is minimized, transfusions will be much safer. With advancements in AI, this technology may completely transform the whole process of diagnosis of donor transfusion, bringing about quicker, more reliable screening.
• Advancements in Nucleic Acid Testing: NAT has been developed as an essential tool to identify pathogens in the blood donated. The NAT methods enable detection of viral infections, such as HIV and hepatitis, with high sensitivity, thus making blood products safe for transfusion. In most regions, NAT is now becoming part of routine testing procedures and is helping in improving the quality of donated blood and reducing the risk of transfusion-transmitted infections. Expanding the usage of NATs is contributing considerably to the worldwide drive for safer blood transfusion practices.
• Transition to Automated Blood Screening Systems: Automation is changing how screening for blood takes place. Many high volume tests are currently done with great precision by utilizing the automated systems used for testing of blood, where many manual processes that are there will be bypassed. Automation facilitates easy completion, lowers the costs associated with human labor, and minimizes human error thus fast and highly accurate tests take place. Automated operations in the case of screening also enhance scalability: that is it is easy to increase volumes, allowing a number of donations at high safety levels.
• Focus on Pathogen Inactivation Technologies: Pathogen inactivation technologies are being increasingly used in the pursuit of safe blood transfusions. It is a method that aims to neutralize the presence of any pathogens within donated blood without compromising its quality. The emerging infectious diseases and multi-drug resistant organisms have increased the demand for advanced inactivation methods. With this extra layer of protection, pathogen inactivation technologies are becoming integral to the diagnosis and processing workflow of donor transfusion.
• Regulatory Changes and Higher Standards: The regulatory agencies across the world have been updating and strengthening the requirements for blood donation and transfusion diagnosis. More stringent screening processes and newer technologies for diagnostic processes are being integrated into the blood donation process. Regulatory changes have compelled the market to innovate and take on a higher level of safety, hence high-quality blood products. Changes in regulation also present opportunities for companies developing innovative diagnostic tools that help in the provision of safer donations of blood.

Emerging trends in the donor transfusion diagnosis market, such as AI integration, advancements in nucleic acid testing, automation, and pathogen inactivation technologies, are enhancing the efficiency, accuracy, and safety of blood screening. These innovations are significantly improving diagnostic processes, reducing risks associated with transfusions, and streamlining blood management. As these trends continue to evolve, they will reshape the market, contributing to higher standards of safety and operational efficiency in blood transfusion practices worldwide.

Recent Developments in the Donor Transfusion Diagnosis Market

Recent advances in the donor transfusion diagnosis market highlight the greater importance now placed on enhancing the safety of blood, diagnosis, and operational efficiency. Technologies and research inputs increasingly streamline the diagnostic process and improve pathogen detection capabilities while ensuring better quality blood products. Five advances currently drive the market are as follows:

• AI-Based Blood Screening: Artificial intelligence has become integral in advancing blood screening methods. AI algorithms now assist in identifying potential incompatibilities, abnormalities, and pathogens in blood donations. This helps to ensure higher accuracy and faster results compared to traditional manual methods. As AI continues to evolve, its potential for improving donor screening and transfusion safety grows, making it a cornerstone of future blood testing innovations.
• Advances in Nucleic Acid Testing (NAT): Nucleic acid testing (NAT) has improved dramatically, with new techniques that allow for the faster and more accurate detection of viral pathogens in blood donations. The increased use of NAT in routine screening has drastically reduced the risk of transfusion-transmitted infections, thereby improving the overall safety of blood transfusions worldwide. The continued refinement of NAT technology is poised to further enhance the detection capabilities of these diagnostic tools.
• Implementation of Automated Screening Systems: The increasing adoption of automated blood screening systems is changing the market by increasing throughput and minimizing human errors. These systems offer faster processing times, enabling large volumes of blood donations to be tested efficiently. The automation of testing processes helps reduce operational costs, minimize risks associated with manual handling, and improve the overall reliability of blood screening procedures.
• Next-Generation Sequencing (NGS) for Pathogen Detection: Advanced screening of blood would be achieved in third-generation sequencing in which NGS technologies are put into blood testing to provide ultrahigh-sensitivity and high selectivity pathogen detection. For instance, wide-ranging infections as rare and recently emerging pathogens were identified with significant accuracy than others. This could be a safety check for blood donated as the diseases that have not been known of before are fast increasing in menace.
• More Advanced Blood Kits: New diagnostic kits designed for screening blood have been made to make the testing more precise, faster, and cheaper. The kits can now be made available in the hospitals as well as remote locations; thus, there is an enhanced possibility of improvement in the safety of blood transfusions in underdeveloped countries.

Recent advancements in the donor transfusion diagnosis market, based on AI-powered screening, advanced pathogen detection, automation, and improved diagnostic kits, are improving blood safety and testing accuracy. These innovations are also reducing operational costs and testing time, driving the market towards more efficient and scalable solutions. As these technologies become more integrated into global blood transfusion systems, they will continue to improve the overall safety and management of blood donations.

Strategic Growth Opportunities in the Donor Transfusion Diagnosis Market

The donor transfusion diagnosis market offers many strategic growth opportunities for companies and healthcare service providers. The increasing demand for safe blood products, advancements in technology, and the necessity of more efficiency in transfusion practices have a wide range of applications where companies can capitalize on emerging trends. Five key growth opportunities across different applications in the market are given below:

• AI-Based Diagnostic Solutions Expansion: AI-driven solutions for donor screening and pathogen detection are expected to revolutionize the market. Companies that invest in these technologies can create even more precise, efficient, and scalable diagnostic platforms. AI can reduce test time substantially, improve the chances of compatibility matching, and enhance safety by identifying potential risks early. The widespread adoption of AI-based tools in the diagnosis of blood transfusion will open new business opportunities and improve patient outcomes.
• Expansion of Blood Management Programs: The demand for blood management systems is increasing as hospitals and blood banks look to optimize blood usage. These systems ensure that blood transfusion services are used efficiently, minimizing waste and ensuring that patients receive the right type of blood. The expansion of blood management programs, particularly in hospitals, presents significant opportunities for businesses providing diagnostic tools and software to improve blood screening, inventory, and donor management.
• Growing Demand for Pathogen Detection Technologies: The demand for advanced pathogen detection technologies, such as NAT and PCR, is increasing due to the growing concerns over emerging infectious diseases. Companies that are developing next-generation pathogen detection tools will have opportunities to address these safety concerns in blood donation systems. In addition, pathogen inactivation technologies are opening new avenues for growth by further enhancing transfusion safety.
• Adoption of Automation in Blood Screening: Automated blood screening technologies are an opportunity for growth. These systems minimize labor, improve accuracy, and increase throughput. As the need for blood donations is increasing around the world, fast, reliable, and scalable testing will be needed. Providers of automated screening technologies will be instrumental in meeting that need.
• Focus on Emerging Markets: Asia and Africa are major growing markets where donors transfusion diagnosis companies will enjoy significant growth potential. Their health infrastructure is rapidly expanding and there is significant investment in the improvement of blood safety. In entering these markets, companies will enjoy new streams of revenue, coupled with opportunities for contributing to international blood safety.

Major opportunities in the donor transfusion diagnosis market would include AI-based diagnostic solutions, expansion of blood management programs, advancements in pathogen detection, and automation, coupled with entry into emerging markets. These opportunities enable companies to further develop more efficient, affordable, and scalable solutions for improving the overall safety and practice of transfusion. Increased demand for better and more effective blood management systems will drive forward this strategic area.

Donor Transfusion Diagnosis Market Driver and Challenges

The donor transfusion diagnosis market is affected by many technological, economic, and regulatory factors. Some drivers are propelling this market forward, but regulatory hurdles, high costs, and infrastructure limitations remain some of the challenges. To help companies understand the challenges and drivers for navigating this market, below are the major drivers and challenges.

The factors responsible for driving the donor transfusion diagnosis market include:

1. Technological Advancements: Advances in diagnostic technologies include AI, nucleic acid testing, and automation. These will enhance the speed, accuracy, and efficiency with which blood is screened, thus resulting in safer transfusions. Also, they reduce operational costs, making it easier for the hospitals and the blood banks to manage blood donations more effectively.

2. Increasing Demand for Safe Blood: Increasing demand for safe blood products from population growth, aging populations, and more frequent medical procedures has become the major factor behind the increasing need for advanced donor transfusion diagnostic solutions. Such a demand would sustain the market's growth in the coming years, mainly in the regions of high healthcare demand.

3. Regulatory Pressure: Strengthening safety standards for blood donations and transfusions by governments and regulatory bodies will establish strong demand for more credible diagnostic tools. With stricter regulatory requirements, the companies need to innovate to meet these standards, leaving room for growth ahead.

4. Increased Transfusion Safety Awareness: Increased awareness of risk with transfusion is forcing service providers to undertake better diagnostic approaches in order to provide safe blood. This forces increased adoption levels of advanced screening technology.

5. Improved Health Infrastructure: The healthcare system, particularly in emerging markets, is experiencing expansion. Therefore, there is a growing demand for more effective blood diagnostic solutions. The increase in the number of hospitals and blood banks requires the establishment of more efficient and reliable blood screening and transfusion systems.

Challenges in the donor transfusion diagnosis market are:

1. High Cost of Advanced Technologies: One of the key challenges is the high cost of implementing advanced diagnostic technologies, which may limit their adoption in developing regions or smaller healthcare settings. The reduction of costs without compromising the efficacy of these technologies will be essential for broader application.

2. Regulatory Compliance: Companies operating internationally may have difficulties complying with the varying standards of different regulatory regions. Onerous and sophisticated regulations can significantly delay the release of new products as well as cost more to run, making access to the market difficult.

3. Infrastructure Limitations in Emerging Markets: In some emerging markets, limited infrastructure and lack of skilled personnel are barriers to the adoption of advanced diagnostic technologies. It will require considerable investment in training and infrastructure development to overcome these challenges.

The donor transfusion diagnosis market is driven by technological advancements, regulatory changes, and increasing demand for blood safety. However, challenges such as high costs and regulatory complexities continue to pose barriers. Companies that navigate these drivers and challenges effectively will find significant opportunities for growth, particularly through innovation and by expanding into emerging markets. As the market evolves, these factors will continue to reshape how blood transfusions are managed globally, ensuring safer and more efficient practices.

List of Donor Transfusion Diagnosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies donor transfusion diagnosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the donor transfusion diagnosis companies profiled in this report include-

• Grifols
• F. Hoffmann-La Roche
• Abbott
• Bio-Rad Laboratories
• Werfen
• Quidelortho Corporation
• Alivedx Holdings Finance
• Bag Diagnostics Gmbh
• Diasorin
• Prestige Diagnostics

Donor Transfusion Diagnosis Market by Segment

The study includes a forecast for the global donor transfusion diagnosis market by type, application, and region.

Donor Transfusion Diagnosis Market by Type [Value from 2019 to 2031]:

• Instruments
• Kits and Reagents

Donor Transfusion Diagnosis Market by Application [Value from 2019 to 2031]:

• Blood Banks
• Blood Donation
• Others

Donor Transfusion Diagnosis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Donor Transfusion Diagnosis Market

Recent developments in the donor transfusion diagnosis market have been driven by advancements in technology, regulatory frameworks, and increasing demand for blood safety and compatibility testing. This market includes innovations aimed at improving diagnostic accuracy, reducing the risk of transfusion-related complications, and optimizing donor screening procedures. Key players in this sector are introducing cutting-edge solutions, including automation, artificial intelligence, and next-generation diagnostic tools. These are some of the advancements since blood transfusion practices are advancing to meet growing needs for safe and efficient blood management, especially for high transfusion-demanding countries such as the United States, China, Germany, India, and Japan.

• United States: In the United States, the donor transfusion diagnosis market has been highly developed, especially when automation and machine learning technologies were introduced. The FDA has been working to improve the standards of blood screening, which in turn has led to more reliable diagnostic tools. Companies are increasingly adopting high-throughput screening technologies that reduce testing times and costs. Advances in NAT also improve the detection of infectious agents in blood donations, providing a higher level of safety for recipients. In summary, the U.S. market is adopting technological advances to improve diagnostic procedures while also ensuring that donor-transfusion compatibility is established.
• China: China's donor transfusion diagnosis market is increasing rapidly because of the country's aging population and increased number of medical interventions. The government in China has increased blood safety standards, hence strict screening measures on blood donation are being conducted. Moreover, introduction of next generation diagnostic technologies that also encompass multiplex PCR testing is simultaneously detecting different kinds of pathogens in the body. China is now experiencing an upward trend in Blood management programs coupled with AI based optimization of blood donors' management in the country, and all of these factors result in a healthy and efficient Blood transfusion systems in the whole country.
• Germany: Germany is known for its highly developed healthcare system, and its donor transfusion diagnosis market is marked by a strong emphasis on regulatory compliance and technological advancement. The use of next-generation sequencing (NGS) and PCR-based testing methods has enhanced the accuracy and speed of donor screening, ensuring blood safety. Additionally, Germany is investing in research to develop more efficient diagnostic platforms that reduce time and cost. The market also benefits from strong collaborations between healthcare providers, government agencies, and diagnostic companies, which are continually refining processes to improve blood transfusion safety and management.
• India: India's donor transfusion diagnosis market is growing due to an expanding healthcare infrastructure and increasing awareness of blood safety. The government has introduced new policies to standardize blood donation screening processes, contributing to improved safety. Automated blood screening devices, and now affordable kits, are proving beneficial in increased test accuracy without increasing the error level. India also increasingly adopts a superior diagnostic test known as NAT in place of routine culturing or staining for increased sensitivity in detection of pathogens. Such changes are expected in India along with the expansion in the utilization of blood and its products for safe transfusion purposes.
• Japan: Donor Transfusion Diagnosis In Japan, in particular, Donor Transfusion Diagnosis is rising steadily and depends on the general healthcare infrastructure along with an interest of precision medicine prevailing in this region. This includes the integration of gene sequencing to improve donor screen accuracy. A country investing money in an upgrading process, mostly in relation to the entire overall efficiency of management systems and through automated testing machinery that helps them reduce the time and processing. Japan's rigorous regulatory environment ensures that diagnostic practices meet the highest standards, and innovations in pathogen detection are enhancing transfusion safety, especially in light of recent challenges posed by emerging infectious diseases.

Features of the Global Donor Transfusion Diagnosis Market

Market Size Estimates: Donor transfusion diagnosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Donor transfusion diagnosis market size by type, application, and region in terms of value ($B).

Regional Analysis: Donor transfusion diagnosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the donor transfusion diagnosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the donor transfusion diagnosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the donor transfusion diagnosis market by type (instruments and kits and reagents), application (blood banks, blood donation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Donor Transfusion Diagnosis Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Donor Transfusion Diagnosis Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Donor Transfusion Diagnosis Market by Type
  • 3.3.1: Instruments
  • 3.3.2: Kits and Reagents
• 3.4: Global Donor Transfusion Diagnosis Market by Application
  • 3.4.1: Blood Banks
  • 3.4.2: Blood Donation
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Donor Transfusion Diagnosis Market by Region
• 4.2: North American Donor Transfusion Diagnosis Market
  • 4.2.1: North American Market by Type: Instruments and Kits and Reagents
  • 4.2.2: North American Market by Application: Blood Banks, Blood Donation, and Others
• 4.3: European Donor Transfusion Diagnosis Market
  • 4.3.1: European Market by Type: Instruments and Kits and Reagents
  • 4.3.2: European Market by Application: Blood Banks, Blood Donation, and Others
• 4.4: APAC Donor Transfusion Diagnosis Market
  • 4.4.1: APAC Market by Type: Instruments and Kits and Reagents
  • 4.4.2: APAC Market by Application: Blood Banks, Blood Donation, and Others
• 4.5: ROW Donor Transfusion Diagnosis Market
  • 4.5.1: ROW Market by Type: Instruments and Kits and Reagents
  • 4.5.2: ROW Market by Application: Blood Banks, Blood Donation, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Type
  • 6.1.2: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Application
  • 6.1.3: Growth Opportunities for the Global Donor Transfusion Diagnosis Market by Region
• 6.2: Emerging Trends in the Global Donor Transfusion Diagnosis Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Donor Transfusion Diagnosis Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Donor Transfusion Diagnosis Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Grifols
• 7.2: F. Hoffmann-La Roche
• 7.3: Abbott
• 7.4: Bio-Rad Laboratories
• 7.5: Werfen
• 7.6: Quidelortho Corporation
• 7.7: Alivedx Holdings Finance
• 7.8: Bag Diagnostics Gmbh
• 7.9: Diasorin
• 7.10: Prestige Diagnostics